JT:4503 Astellas Pharma Inc
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. The company has a collaboration with Actinium Pharmaceuticals, Inc. to apply Actinium warhead enabling technology platform for generating Actinium radio-conjugates with various Astellas targeting agents; and a research collaboration with NapaJen Pharma, Inc. for the discovery and development of oligonucleotide therapeutics. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.This company has ADRs that trade in the U.S. as the symbol ALPMY.
1,845.00 JPY
As of 03/24/2023
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Health Care
Industry: Drug Manufacturers-General
Index country: Japan
Country of incorporation: Japan
IPO date: 01/04/1984
Stock exchange: Tokyo Stock Exchange
Exchange country: Japan
Market cap: 3,582,720,475,136 JPY
Current dividend yield: 3.01%
Sedol: 6985383